11 new research advances from the past year
Over the past year, MD Anderson researchers and clinicians have investigated the gut microbiome, examined the earliest genesis of lung adenocarcinoma cells, tested new and improved therapies, and more. Their breakthroughs in cancer research continue to drive forward our mission to end cancer.
Here are 11 novel MD Anderson research highlights from last year.
1. Eating beans improves gut health, regulates immune and inflammatory...
Advances in small cell lung cancer classification
Most patients with lung cancer have non-small cell lung cancer. However, around 15% of patients have a less-common type called small cell...
What is theranostics?
You may have heard the term theranostics when reading about cancer treatments, but what does it mean? The word theranostics is a combination...
Innovative directions in immunotherapy research
Immunotherapy is a cancer treatment that uses a patient’s immune system to target their cancer cells. Some common types of immunotherapies are immune checkpoint therapy, chimeric antigen receptor (CAR) T cell therapy and monoclonal antibodies.
But researchers are doing lots of other interesting things with immunotherapy, from preventing cancer to treating rare cancer types to making cancer treatments more effective. We spoke...
How are targeted therapies used in lung cancer treatment?
Lung cancer is the third-most common type of cancer and the most common cause of cancer-related deaths in the United States, according to...
What’s new in leukemia research?
Leukemia is an overarching term encompassing several subtypes of blood cancers. Blood cells are produced in the bone marrow, the spongy material...
What are PARP inhibitors?
PARP inhibitors are a type of targeted therapy commonly used to treat breast cancer and ovarian cancer, among others. They target PARP, or...